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Abstract
Background and objective: The objective of this article is to externally validate and update a recently published score chart
for chronic mesenteric ischemia (CMI).
Methods: A multicenter prospective cohort analysis was conducted of 666 CMI-suspected patients referred to two Dutch
specialized CMI centers. Multidisciplinary consultation resulted in expert-based consensus diagnosis after which CMI con-
sensus patients were treated. A definitive diagnosis of CMI was established if successful treatment resulted in durable
symptom relief. The absolute CMI risk was calculated and discriminative ability of the original chart was assessed by the c-
statistic in the validation cohort. Thereafter the original score chart was updated based on the performance in the combined
original and validation cohort with inclusion of celiac artery (CA) stenosis cause.
Results: In 8% of low-risk patients, 39% of intermediate-risk patients and 94% of high-risk patients of the validation cohort,
CMI was diagnosed. Discriminative ability of the original model was acceptable (c-statistic 0.79). The total score of
the updated chart ranged from 0 to 28 points (low risk 19% absolute CMI risk, intermediate risk 45%, and high risk
92%). The discriminative ability of the updated chart was slightly better (c-statistic 0.80).
Conclusion: The CMI prediction model performs and discriminates well in the validation cohort. The updated score chart has
excellent discriminative ability and is useful in clinical decision making.
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Key summary
1. What is the current knowledge?
. Chronic mesenteric ischemia (CMI) is the result of insuﬃcient mucosal perfusion of the gastrointestinal
tract.
. The diagnosis of CMI is established by multidisciplinary consensus and conﬁrmed if successful therapy
results in symptom relief.
. A recently published prediction model identiﬁes low-risk, intermediate-risk and high-risk patients for
CMI.
2. What is new here?
. Validation of the previously published prediction model in a new multicenter cohort shows good
performance with acceptable discriminative ability.
. An updated score chart has been designed with the following predictors: presence of weight loss,
presence of cardiovascular disease, the degree of celiac artery (CA) stenosis combined with the cause
of CA stenosis and the degree of superior mesenteric artery stenosis.
. The updated score chart performs well with excellent discriminative ability and deﬁnes a low-risk group
with absolute CMI risk of 19%, an intermediate-risk group with a 45% CMI risk and a high-risk group
with a 92% CMI risk.
. The updated score chart is a useful tool to be used in clinical practice to stratify CMI-suspected patients
in three groups: 1. wait-and-see policy justiﬁed, 2. additional functional testing indicated, and 3. imme-
diate vascular intervention justiﬁed.
Introduction
Chronic mesenteric ischemia (CMI) is deﬁned as ische-
mic symptoms caused by insuﬃcient blood supply of
the gastrointestinal tract.1 The most common cause is
atherosclerotic stenosis of one or more supplying
gastrointestinal arteries.1,2 Other common causes for
mesenteric artery stenosis are vasculitis, and the most
common cause of isolated celiac artery (CA) stenosis is
compression of the CA by the median arcuate ligament
(median arcuate ligament syndrome (MALS)). Chronic
nonocclusive mesenteric ischemia (NOMI) is caused by
hypoperfusion or hypooxygenation as can be seen in
underlying conditions such as cardiac or pulmonary
disease, shunting, microvascular occlusion, and auto-
nomic dysfunction.3
The exact incidence of CMI is unknown, since popu-
lation-based studies are lacking. However, the number
of CMI patients undergoing revascularization proced-
ures is increasing signiﬁcantly according to data from
the United States (1.8 per million in 2000 to 5.6 per
million in 2012 (p< 0.01)).4 Considering the aging
population and the increased prevalence of cardiovas-
cular disease (CVD), the incidence of CMI is expected
to increase in upcoming years.
Diagnosing CMI is important since untreated CMI
may develop into acute-on-chronic mesenteric ische-
mia, which is associated with high morbidity and mor-
tality. Since no gold-standard test for CMI is currently
available, the diagnostic work-up consists of symptom
assessment and radiological evaluation of the mesen-
teric arteries.3 Symptoms alone are associated with a
low predictive value for CMI.2,5,6 If available,
a functional test to assess mucosal ischemia such as
gastric-jejunal tonometry7–9 or visible light spectros-
copy (VLS)10,11 can enhance diagnostic accuracy.
A consensus diagnosis is established in a multidisciplin-
ary meeting,1 an accepted method in the absence of one
speciﬁc test.12 A deﬁnitive diagnosis of CMI is estab-
lished when revascularization for occlusive mesenteric
ischemia or medical therapy for chronic NOMI results
in durable symptom relief.
The diagnostic work-up for CMI is cumbersome and
time consuming since multiple tests are required. This
exposes patients to invasive diagnostic interventions
and because of the need for successive investigations
may lead to a delay in treatment for patients with
CMI. This underlines the need for an easy-to-use tool
to promptly and reliably assess the risk of CMI in
patients suspected of having this diagnosis to guide
clinical decision making: 1) patients with low risk of
CMI for whom a wait-and-see policy is justiﬁed to
save them from unnecessary diagnostics, 2) patients
with intermediate risk of CMI for whom further testing
to assess mucosal oxygenation such as VLS or tonome-
try is indicated to establish the diagnosis and 3) patients
with high risk of CMI for whom no additional test is
indicated and who require intermediate vascular
intervention.
Recently, a CMI prediction model based on a large,
single-center prospective cohort was published by our
study group that identiﬁes low-risk, intermediate-risk
and high-risk patients.13 The score chart of this model
consists of ﬁve predictors: female sex, presence of
weight loss, presence of CVD, degree of CA stenosis,
and degree of superior mesenteric artery (SMA)
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stenosis (Table 1). However, this CMI prediction model
did not include the cause of the CA stenosis, such as
MALS or atherosclerosis, which diﬀer in patient pres-
entation and patient characteristics.2 Since it was
expected by experts in the ﬁeld that the speciﬁc cause
of CA stenosis would result in diﬀerent predictive
values for the risk of CMI, this variable was added to
the updated model.
The current diagnostic work-up for CMI is extensive
and cumbersome. A validated tool is much needed to
stratify patients suspected of having CMI in distinct
risk groups to guide clinical decision making. Such a
tool and corresponding strategy should result in a more
optimal identiﬁcation of patients with CMI who may
proﬁt from treatment using tailored diagnostics and
should lead to a decrease in patient burden and reduced
health costs. We aimed to externally validate the previ-
ously published CMI prediction model in a new multi-
center cohort. Furthermore, we aimed to update the
score chart based on the performance of the model by
combining the original and validation cohort and by
including the CA stenosis cause.
Material and methods
Study design and setting of validation cohort
A multicenter, prospective cohort study was conducted
for all consecutive patients suspected of CMI referred
to two Dutch centers specializing in functional testing
for mucosal ischemia: Erasmus MC University Medical
Center Rotterdam (inclusion January 2014 to July
2016) and Medisch Spectrum Twente Enschede (inclu-
sion May 2015 to January 2016). Patients were sus-
pected of having CMI based on the criteria for the
original cohort of Harki et al.13 Patients without radio-
logical evaluation of the mesenteric arteries with com-
puted tomography angiography (CTA) or magnetic
resonance angiography (MRA) were excluded.
The medical research ethics committee of Erasmus
MC University Medical Center approved that the
Medical Research Involving Human Subjects Act
does not apply to this study and that no informed con-
sent was required according to local directives (MEC-
2013-317). The study complies with the Declaration of
Helsinki on research ethics. To enhance transparency
this article is written according to the Strengthening the
Reporting of Observational Studies in Epidemiology
checklist for cohort studies.14
Data sources
All data were retrieved from the hospital records in the
context of standard clinical care. Follow-up of patients
was by means of outpatient clinic contact or by phone.
Standard protocol visits were scheduled 1, 3, 6, 12, and
24 months after revascularization during which recur-
rent symptoms (i.e. similar to presenting symptoms
before therapy) were assessed and body weight was
documented.
Participants
All included patients underwent a standardized diag-
nostic work-up for CMI at baseline. This work-up con-
sists of symptom assessment, physical examination,
imaging of the mesenteric arteries with either CTA
and MRA, and a functional test for mucosal ischemia
detection with either 24-hour gastric-jejunal tonometry,
gastric exercise tonometry or VLS.6–8,10,15–17
All cases were discussed in a multidisciplinary meet-
ing attended by gastroenterologists, vascular surgeons
and interventional radiologists, all specializing in CMI.
An expert-based consensus diagnosis of CMI was
established if two of the following three criteria were
met: 1) typical clinical presentation of CMI (postpran-
dial abdominal pain, weight loss, or diarrhea); 2) sig-
niﬁcant stenosis of at least the CA or SMA (50%
diameter reduction18–21) on CTA or MRA and/or con-
ventional catheter angiography; 3) mucosal ischemia as
determined by 24-hour gastric-jejunal tonometry, gas-
tric exercise tonometry or VLS.7,10
Table 1. Score chart for the prediction of CMI and the absolute
CMI risk from Harki et al.13
Predictor Scoring points
Sex
Male 0
Female 1
Weight loss
No 0
Yes 1
Cardiovascular disease
No 0
Yes 1
Celiac artery
50%–70% stenosis 1
>70% stenosis 4
Superior mesenteric artery
50%–70% 1
>70% stenosis 3
Total score Risk group Absolute CMI
risk (%)
0–2 points Low 21%
3–6 points Intermediate 46%
7þ High 79%
CMI: chronic mesenteric ischemia.
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The degree of stenosis of the mesenteric arteries was
calculated on CTA or MRA using interactive vessel
segmentation software. The stenosis degree was classi-
ﬁed as <50% stenosis, 50%–70% stenosis or 70%
stenosis.
Definitive diagnosis of CMI
Patients with a consensus diagnosis of CMI based on
occlusive disease were scheduled for either endovascu-
lar or surgical revascularization. Patients with stenosis
of one or more mesenteric arteries based on vascular
disease were scheduled ﬁrst for endovascular revascu-
larization: percutaneous mesenteric artery stenting
(PMAS). If patients were not eligible for PMAS or if
patients had recurrent episodes of restenosis, they were
treated with open surgical mesenteric artery repair
(OSMAR).
In patients with a CA stenosis, the diagnosis of
MALS was established if CTA demonstrated focal nar-
rowing of the proximal CA 50% with poststenotic
dilatation and eccentric indentation on the superior
aspect of the CA, creating a hook-shaped contour of
the CA. This characteristic kinking dependent on the
respiratory cycle in the absence of calciﬁcations distin-
guishes this condition from other causes of CA stenosis
such as atherosclerosis.22 When CTA did not clarify the
cause of CA stenosis, an additional catheter angiog-
raphy of the CA in inspiration and expiration was per-
formed. Patients with CA stenosis based on MALS
were planned for surgical release (open or endoscopic)
of the median arcuate ligament.
Patients with a consensus diagnosis of chronic
NOMI were treated with vasodilatory medical therapy:
oral nitrates (isosorbide mononitrate or isosorbide dini-
trate). First, a low dose was prescribed (10–20mg twice
per day) and if symptoms persisted with the absence of
side eﬀects the dose was increased (to 40mg twice per
day). Nitrates were replaced by Ketanserin (selective
a1-receptor antagonist) if side eﬀects occurred and/or
clinical improvement was absent, starting with
10–20mg twice per day and increased to 40mg twice
per day.
The treated patients were evaluated during follow-up
visits. A deﬁnitive diagnosis of CMI was established if
the patient reported relief of initial symptoms after suc-
cessful therapy. This patient-reported outcome of
symptom relief was classiﬁed into two groups: no or
minimal symptom relief and major or complete
symptom relief. A deﬁnitive diagnosis of no CMI was
established when consensus diagnosis was no CMI or
when symptom relief did not occur after technically
successful treatment. Patients with a consensus
diagnosis of no CMI were discharged without further
follow-up.
Variables
Patient characteristics that were collected included age,
sex, past medical history, presenting symptoms such as
abdominal pain, postprandial pain, diarrhea, nausea,
weight loss (in kg, deﬁned as >5% loss of body
weight), body mass index (BMI) at presentation and car-
diovascular risk factors. Vascular lesions were speciﬁed
for localization (CA, SMA or inferior mesenteric artery
(IMA)) and cause (vascular disease, MALS, NOMI).
The primary outcome was deﬁnitive diagnosis: CMI
or no CMI. The deﬁnitive diagnosis was compared with
the total score of the score chart to validate this score
chart. Secondary outcome was the cause of CMI (vas-
cular disease vs MALS).
Score chart
The score chart (Table 1) was applied for each included
patient. Based on the total score each patient was clas-
siﬁed in one of three risk groups: low-risk (0–2 points),
intermediate-risk (3–6 points) and high–risk (7
points).
Study size
There was a requirement to include minimally 215
patients suspected of having CMI assuming a CMI
diagnosis rate of 47%13 according to literature recom-
mendations on sample size considerations for the exter-
nal validation of a multivariable prognostic model.23,24
Statistical methods
Baseline characteristics were described for the valid-
ation cohort either as numbers and percentages for
dichotomous variables, or as means and standard devi-
ations or medians and interquartile ranges (IQR) for
continuous variables. Multiple imputation (10 times)
was used to impute missing values of the predictors
from the score chart and cause of CA stenosis.
Univariable and multivariable associations were esti-
mated with logistic regression analysis as odds ratios
(ORs) with a 95% conﬁdence interval (CI). The
added value of cause of the stenosis of the CA (vascular
disease vs MALS) was assessed by including the vari-
able in the multivariable logistic regression.
Performance of the original score chart was studied
by comparing the deﬁnitive diagnosis with the total score
of the score chart. Discriminative ability of the score
chart was assessed with the c-statistic. This measure of
concordance is identical to the area under the receiver-
operating characteristics (ROC) curve. C-statistic of 0.5
suggests no discrimination, c-statistic of 0.7–0.8 is con-
sidered as acceptable discrimination, c-statistic of 0.8–0.9
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as excellent discrimination and c-statistic 0.9 as out-
standing discrimination.25 Furthermore, calibration
was assessed graphically with a calibration plot: a plot
with the predicted risk of CMI on the X-axis and the
observed proportion of CMI on the Y-axis. After vali-
dating the score chart in the validation cohort, the data
of the validation cohort was combined with the data of
the original cohort described by Harki et al.13 The ori-
ginal score chart was updated based on the performance
of the score chart in the combined original cohort and
validation cohort and with inclusion of the cause of
the CA stenosis based on expert view. Scores for the
updated score chart were calculated by dividing the
regression coeﬃcients of the predictors by 0.17.
Calibration and discriminative ability were also tested
for the updated score chart.
Results
Patient characteristics of validation cohort
During the study period, 246 patients suspected of
having CMI were included in the validation cohort. A
consensus diagnosis of CMI was established in 105/246
patients (43%). After treatment for CMI, a deﬁnitive
diagnosis of CMI was established in 93/105 patients
(89%). A ﬂowchart is shown in the supplementary
material. Mean age in the validation cohort was
61 years, the majority were female (70%), with a
mean symptom duration of two years (Table 2).
Table 3 lists the consensus diagnosis, deﬁnitive diagno-
sis, vascular lesions, and cause of stenosis for each risk
group according to the original score chart in the val-
idation cohort. The majority of patients in the low-risk
group did not have signiﬁcant vascular lesions (75%)
whereas all patients in the high-risk group had at least
one signiﬁcant mesenteric stenosis, 96% being athero-
sclerotic. Furthermore, the majority of patients in the
high-risk group had multivessel disease (88%).
The follow-up period was 10.5 6.6 months for the
patients with a consensus diagnosis of CMI and
3.7 6.6 months for the patients with a consensus diag-
nosis of no CMI.
Performance original score chart
The original score chart performed well in the valid-
ation cohort with an absolute CMI risk of 8% in the
Table 2. Patient characteristics and presenting symptoms of validation cohort.
All patients
n¼ 246
Definitive diagnosis
of CMI n¼ 93
No definitive
diagnosis of CMI
n¼ 153
Patient characteristics
Age (y) 60.9 16.6 65.8 14.4 57.9 17.2
Female 171 (69.5%) 58 (62.4%) 113 (73.9%)
Hypertensiona 122 (49.6%) 62 (66.7%) 60 (39.2%)
Ever smoked 179 (73.7%) 79 (85.9%) 100 (66.2%)
Dyslipidemiab 123 (50.2%) 62 (67.4%) 61 (39.9%)
Diabetes 42 (17.1%) 25 (26.9%) 17 (11.1%)
BMI at presentation (kg/m2) 23.5 4.8 23.5 5.1 23.4 4.6
History of CVD 133 (54.1%) 68 (73.1%) 65 (42.5%)
Presenting symptoms
Symptom duration (months) 23.6 59.3 18.0 31.4 27.1 71.1
Abdominal pain 231 (93.9%) 88 (94.6%) 143 (93.5%)
Postprandial pain 166 (67.8%) 65 (70.7%) 101 (66.0%)
Exercise-related pain 78 (35.0%) 23 (28.7%) 55 (38.5%)
Nausea 128 (57.9%) 51 (60.0%) 77 (56.6%)
Diarrhea 72 (30.6%) 32 (36.8%) 40 (27.0%)
Weight loss 169 (68.7%) 76 (81.7%) 93 (60.8%)
BMI: body mass index; CMI: chronic mesenteric ischemia; CVD: cardiovascular disease.
Data are presented as N (percentages) or as mean SD.
aHypertension was defined as a blood pressure of 140/90 mmHg or use of antihypertensive medication.
bDyslipidemia was defined as low-density lipoprotein cholesterol> 4.2 mmol/l or high-density lipoprotein cholesterol< 0.9 mmol/l
or use of lipid-lowering medication.
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low-risk group (original cohort: 21%13), 39% in the
intermediate-risk group (original cohort: 46%13) and
94% in the high-risk group (original cohort: 79%13).
Discriminative ability was acceptable with a c-statistic
of 0.79 (original cohort: 0.79). Calibration results of the
original model in the combined cohort are shown in
Figure 1(a). Perfect prediction of CMI would show
when all points are at 45 degrees (dashed line) because
of a slope of 1 and calibration intercept of 0.
Combined cohort
The observed frequencies of CMI in the original cohort,
validation cohort and combined cohort are shown in
Table 4 speciﬁed per hospital. The frequency of CMI
was higher in the original cohort (47%) than in the
validation cohort (38%). Table 5 shows the multivari-
able logistic regression analyses of the combined cohort
with the ﬁve predictors of the original score chart and
with interaction of the CA stenosis cause (vascular dis-
ease vs MALS). Sex showed no eﬀect in the combined
cohort (female OR¼ 1.01, 95% CI 0.68–1.52).
Updated score chart
Table 6 shows the updated score chart with the absolute
CMI risk. We included the interaction of the CA sten-
osis cause based on expert view, although not statistic-
ally signiﬁcant (p¼ 0.541). The score of the updated
chart ranged from 0 to 28 points, with 0 to 5 points
indicating a low risk of CMI of 19% (low-risk original
score chart in combined cohort: 22%), 6 to 18 points
indicating an intermediate risk of 45% (intermediate-
risk original score chart in combined cohort: 45%) and
19 points or more indicating a high risk of 92% (high-
risk original score chart in combined cohort: 87%). The
low-risk group consisted of 247 of the 666 patients of
the combined cohort (37%), the intermediate-risk
Table 3. Diagnosis, vascular lesion, and cause of the vascular lesion specified for each risk group according original
score chart of the validation cohort.
Low-risk
(0–2 pts)
n¼ 92
Intermediate-risk
(3–6 pts)
n¼ 106
High-risk
(7 pts)
n¼ 48
Diagnosis
Consensus diagnosis CMI 10 (10.9%) 49 (46.2%) 46 (95.8%)
Definitive diagnosis CMI 7 (7.6%) 41 (38.7%) 45 (93.8%)
Cause of vascular lesion
No sign, vascular lesiona, no ischemia 69 (75.0%) 13 (12.3%) 0 (0.0%)
Vascular disease 7 (7.6%) 57 (53.7%) 42 (87.5%)
MALS 7 (7.6%) 33 (31.1%) 2 (4.2%)
NOMI 6 (6.5%) 1 (0.9%) 0 (0.0%)
AtherosclerosisþNOMI 3 (3.3%) 0 (0.0%) 1 (2.1%)
AtherosclerosisþMALS 0 (0.0%) 1 (0.9%) 3 (6.3%)
MALSþNOMI 0 (0.0%) 1 (0.9%) 0 (0.0%)
Vascular lesion localization
No significant vascular lesiona 75 (81.5%) 14 (13.2%) 0 (0.0%)
Single vessel 16 (17.4%) 70 (66.0%) 6 (12.5%)
CA stenosis 10 (62.5%) 52 (74.2%) 5 (83.3%)
SMA stenosis 0 (0.0%) 17 (24.3%) 1 (16.7%)
IMA stenosis 6 (37.5%) 1 (1.4%) 0 (0.0%)
Multivessel 1 (1.1%) 22 (20.8%) 42 (87.5%)
CA and SMA stenosis 0 (0.0%) 9 (40.9%) 16 (38.1%)
CA and IMA stenosis 0 (0.0%) 4 (18.2%) 1 (2.4%)
SMA and IMA stenosis 1 (100%) 6 (27.3%) 0 (0.0%)
CA, SMA and IMA stenosis 0 (0.0%) 3 (13.6%) 25 (59.5%)
CA: celiac artery; CMI: chronic mesenteric ischemia; IMA: inferior mesenteric artery; MALS: median arcuate ligament syndrome;
NOMI: nonocclusive mesenteric ischemia; pts: points; SMA: superior mesenteric artery.
aNo significant vascular lesion¼ no stenosis or stenosis <50%.
Data are presented as n (percentages).
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group of consisted of 305 (46%) patients, and the high-
risk group consisted of 114 (17%) patients.
Figure 1(b) shows the calibration of the updated
score chart. The updated model is based on the data
of the combined cohort and resulted in a calibration
intercept close to 0 and calibration slope b (slope b)
close to 1. The discriminative ability of the updated
model is excellent with a c-statistic of 0.80.
Discussion
In this multicenter study, we performed an external
validation of the recently developed score chart to pre-
dict the risk of CMI. Next, we developed an updated
version of the score chart based on the performance of
the score chart in the combined cohort and with inclu-
sion of the CA stenosis cause. CMI predictors of
the updated score chart are presence of weight loss,
presence of CVD, the degree of CA stenosis combined
with the cause of CA stenosis and the degree of
SMA stenosis. The updated score chart is an easy-
to-use and reliable tool to discriminate the risk of
CMI (c-statistic 0.80).
The ﬁndings of our cohort analysis in 666 CMI sus-
pected patients, the largest cohort described, corres-
pond with the recently published clinical practice
guidelines Management of the diseases of mesenteric
arteries and veins1 by the European Society of
Vascular Surgery. Weight loss is an important symp-
tom for the diagnosis of CMI according to the guide-
lines, and the advice is given to perform additional
analyses for an alternative diagnosis in patients sus-
pected of having CMI without substantial weight loss.
Our data conﬁrm that weight loss is the only predictive
clinical symptom in the prediction model. In accord-
ance with the guidelines stating that patients with
CMI have atherosclerotic involvement in other
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Figure 1. Performance of the (a) original score chart and (b) the updated score chart based on the combined cohort (n¼ 666).
Alb: intercept a; slope b: calibration slope; c stat: c-statistic.
Table 4. Observed frequencies of chronic mesenteric ischemia in original, validation and combined cohorts’ hospital specified.
Center
Original cohort
n¼ 420
Validation cohort
n¼ 246
Combined data
n¼ 666
Erasmus MC University Medical Center 196/420 (46.7%) 42/136 (30.1%) 238/556 (42.8%)
Medisch Spectrum Twente – 51/110 (46.6%) 51/110 (46.6%)
Total 196/420 (46.7%) 93/246 (37.8%) 289/666 (43.4%)
Table 5. Results of multivariable logistic regression analyses in
the combined cohort; odds ratio (95% confidence interval).
Predictors
Combined cohort
n¼ 666
Female 1.01 (0.68–1.52)
Weight loss 2.22 (1.47–3.35)
CVD 1.40 (0.95–2.07)
50%–70% CA stenosis, vascular disease 1.82 (0.96–3.44)
50%–70% CA stenosis, MALS 1.94 (0.77–4.91)
>70% CA stenosis, vascular disease 6.62 (3.95–11.09)
>70% CA stenosis, MALS 4.53 (2.43–8.44)
50%–70% SMA stenosis 2.02 (0.99–4.15)
>70% SMA stenosis 5.94 (3.42–10.31)
CA: celiac artery; CMI: chronic mesenteric ischemia; CVD: cardiovascular
disease; MALS: median arcuate ligament syndrome; SMA: superior mesen-
teric artery.
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locations,26,27 our score chart incorporated the presence
of CVD as a predictor of CMI. Finally, the guidelines
recommend considering the diagnosis of CMI in
patients with otherwise unexplained abdominal symp-
toms and occlusive disease of two or three mesenteric
arteries. This corresponds with our ﬁndings that multi-
vessel disease is present in 88% of high-risk patients as
opposed to only 1% multivessel disease in low-risk
patients.
In contrast with the original score chart, female sex
is not a predictor in the updated score chart. Female
preponderance for CMI is reported in the litera-
ture,26,27 and we show that the majority (70%) of
patients with deﬁnitive CMI are female in the combined
cohort. However, the majority of patients without CMI
are also female (65%).
We recommend the updated model for clinical prac-
tice since it is based on a more heterogeneous data set
from a multicenter cohort, which supports its generaliz-
ability. Its applicability is also boosted by inclusion of
the cause of CA stenosis. Experts expressed reservations
regarding the original score chart because it lacked the
cause of CA stenosis, whereas clinical presentation and
patient characteristics diﬀer between those with athero-
sclerotic CMI and CMI based on MALS. The updated
score chart shows a higher predictive value for vascular
disease in case of greater than 70% CA stenosis.
Both the original and the validation cohort include
patients with chronic NOMI. Patients with NOMI pre-
sent with typical symptoms of CMI. Chronic NOMI
patients, however, will not be readily identiﬁed as high-
risk using the score chart because of a maximum score of
seven points in the absence of mesenteric artery stenoses.
Subsequently, chronic NOMI patients are classiﬁed as
low risk or intermediate risk. Based on symptom devel-
opment, they will undergo immediate or later additional
testing to establish or negate the diagnosis of CMI.
We suggest a wait-and-see policy for patients classi-
ﬁed as low risk by the updated score chart since the
symptoms in this patient group are minor and immedi-
ate treatment is not required. According to the score
chart, 19% of the patients in the low-risk group will
have CMI and their CMI is caused by NOMI or single-
vessel disease. The delay in CMI diagnosis for the 19%
patients suﬀering from CMI in the low-risk group can
be defended since these patients are under the control
of a physician during the wait-and-see policy who may
intervene when the clinical situation during follow-up
worsens. With this wait-and-see strategy, on the other
hand, patients without CMI in the low-risk group
(81%) are spared unnecessary diagnostic procedures.
This study has several limitations. An inevitable limi-
tation is the absence of a gold-standard clinical test for
the diagnosis of CMI. A working diagnosis is established
by multidisciplinary consensus opinion and a deﬁnitive
diagnosis is established when treatment results in dur-
able symptom relief.3 Symptom relief is considered the
most important and relevant patient-related outcome.
This response was noted as a dichotomous variable to
limit interpretation bias. However, the patients reported
symptom relief to the same team that participated in the
multidisciplinary meeting reaching the consensus diag-
nosis of CMI, for which reason reporting bias cannot
be excluded. Patients with a consensus diagnosis of no
CMI were not selected for therapy and discharged with-
out further follow-up. The results of our prediction
model can be extrapolated only to patients suspected
of having CMI. Therefore, this model should not be
used for patients with gastrointestinal symptoms in gen-
eral, but only for those with a clear suspicion of CMI
after other causes have been excluded. Incorporation
bias may have possibly led to overestimation of the diag-
nostic accuracy of the score chart for CMI.28 Finally, the
original cohort described by Harki et al. consisted of 436
patients.13 The data set used for the current combined
cohort analysis consisted of 420 patients from the ori-
ginal cohort because of missing data. In view of the siz-
able number of 666 patients in the current analysis, we
assume that the eﬀect of the missing data of these
16 patients is negligible.
Table 6. Updated score chart for prediction of CMI.
Predictor
Scoring
points
Weight loss
No 0
Yes 5
Cardiovascular disease
No 0
Yes 2
Celiac artery
50%–70% stenosis,
vascular disease
4
50%–70% stenosis, MALS 4
>70% stenosis,
vascular disease
11
>70% stenosis, MALS 9
Superior mesenteric artery
50%–70% stenosis 4
>70% stenosis 10
Total score Risk group Absolute
CMI risk (%)
0–5 points Low 19.4%
6–18 points Intermediate 44.6%
19þ High 92.1%
CMI: chronic mesenteric ischemia; MALS: median arcuate ligament
syndrome.
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In conclusion, we externally validated a previously
published score chart to predict the risk of CMI. We
also updated the original score chart and included the
cause of CA stenosis based on expert view. The updated
score chart shows good performance and an excellent
discriminative ability. This updated score chart is a
useful tool to be used in clinical practice to stratify
CMI-suspected patients in three groups: 1. wait-and-
see policy justiﬁed, 2. additional functional testing indi-
cated and 3. immediate vascular intervention justiﬁed.
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